Mario Santagati

New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer’s disease: focus on brexpiprazole and pimavanserin

Filippo Caraci, Mario Santagati, Giuseppe Caruso et al. · F1000Research · 2020 · 46 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Selective Serotonin Reuptake Inhibitors and Serotonin and Noradrenaline Reuptake Inhibitors Improve Cognitive Function in Partial Responders Depressed Patients: Results from a Prospective Observational Cohort Study

Sabrina Castellano, Salvatore Salomone, Simona De Vivo et al. · CNS & Neurological Disorders - Drug Targets · 2016 · 30 citations

Medicine, Pharmacotherapy, Psychiatry +17

The Apathy Evaluation Scale (AES-C): Psychometric Properties and Invariance of Italian Version in Mild Cognitive Impairment and Alzheimer’s Disease

Giovanna Furneri, Silvia Platania, Alessandra Privitera et al. · International Journal of Environmental Research and Public Health · 2021 · 20 citations · Full text

Medicine, Psychiatry, Psychology +17

Studies on annelated thiazolopyrimidines IV. Synthesis and pharmacological properties of thiazolothienopyrimidine derivatives

Francesco Russo, A. SANTAGATI, Mario Santagati et al. · European Journal of Medicinal Chemistry · 1989 · 18 citations

Pharmacy, Medicinal Chemistry, Pharmacology +8

Advanced AI techniques for classifying Alzheimer’s disease and mild cognitive impairment

Sophie Tascedda, Pierfrancesco Sarti, Veronica Rivi et al. · Frontiers in Aging Neuroscience · 2024 · 13 citations · Full text

Medicine, Geriatric Medicine, Neurology +17